Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already ...

Numerous studies show that single doses may be insufficient because of an individual’s weight, or the severity of the ...

Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, British Columbia–(Newsfile Corp. – February 10, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: ...

Detailed price information for Tempramed Technologies Ltd. (VIVI-CN) from The Globe and Mail including charting and trades.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...

In a nation divided by geography and politics, the United States Interstate Highway System brings us together. It gets us to ...

Kimball Electronics Balances Auto Weakness With Medical Momentum in Upbeat Earnings Call ...

Gerresheimer will present its latest sustainable glass packaging solutions for organic food, natural cosmetics, and nutraceuticals at BIOFACH 2026 in Nuremberg, showcasing flint and amber glass ...